
EVALUATION OF THE JAK2V617F MUTATIONAL BURDEN
IN PATIENTS WITH PHILADELPHIA CHROMOSOME
NEGATIVE MYELOPROLIFERATIVE NEOPLASMS:
A SINGLE-CENTER EXPERIENCE Popova-Labachevska M1, Panovska-Stavridis I1,*, Eftimov A2, Kapedanovska Nestorovska A2,
Cevreska L1, Ivanovski M1, Ridova N1, Trajkova S1, Dimovski AJ2,* *Corresponding Author: Associate Professor Irina Panovska-Stavridis, M.D., Ph.D., University Clinic
of Hematology, UKIM-Faculty of Medicine, University Cyril and Methodious,” Majka Tereza 47, Skopje,
RN Macedonia. Tel/Fax: +38923111749. E-mail: ukhematologija@t.mk and/or Professor Aleksandar J.
Dimovski, M.D., Ph.D., Center for Biomolecular Pharmaceutical Analyses, UKIM-Faculty of Pharmacy,
University “Ss Cyril and Methodius,” Majka Tereza 47, Skopje, RN Macedonia. Tel/Fax: +38923119694.
E-mail: adimovski@ff.ukim.edu.mk page: 31
|
DISCUSSION
In an attempt to explain the association of the single
mutation with three different clinical phenotypes, the genedosage
hypothesis postulates that the ratio between the
mutant type and wild JAK2 type in hematopoietic cells
influences the expression of the clinical phenotype [5-7]. As patients with MPNs often present with overlapping clinical
signs, symptoms and morphological findings, several studies
have been conducted to test this hypothesis [5-7]. They
have shown that the JAK2 mutational load is associated
with specific hematological and clinical parameters in different
MPN entities [9]. It has been suggested that a mutant
allele burden of >50.0% is associated with older age, clinical
signs and symptoms of PV, a more severe clinical course
with a higher rate of thrombosis and a faster progression to
myelofibrosis compared to a mutant allele burden <50.0%
[9,10]. Other studies showed that the JAK2 allele burden
could be used for stratification of patients into subgroups
associated with different frequency of complications [9].
Although, the WHO criteria does not specify a cutoff
value for the diagnosis of a specific MPN, the determination
of the mutational load is becoming a potential diagnostic
procedure in most molecular laboratories worldwide
and, in addition, it may be useful in evaluating the response
to therapy [1]. Another perspective of the evaluation of the
allele burden is its utility as a follow-up tool during the
treatment of JAK2V617F positive patients [9]. However,
the specific utility of the JAK2V617F allele burden for
measuring the MPN patients’ response to treatment is yet
to be established [11].
In our group of patients, there was a statistically significant
difference in the percentage of the mutant allele
between ET and PMF patients (p <0.00001) and between
PV and PMF patients (p <0.05), but not between PV and
ET patients (p = 0.38). These findings are consistent with
several previous studies that showed a significantly higher
JAK2 allele burden in PV and PMF patients in contrast
to ET patients [9].
Several studies have discussed the JAK2 allele burden
impact on disease transformation and its utility in predicting
disease transformation [9,10]. Our results showed that
in the presence of a higher V617F allele burden, a diagnosis
of PV and PMF should be strongly considered, because
the burden of the mutated allele correlates with the MPN
phenotype and a major clinical endpoint [9-11].
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|